Which medications in the drug class Bcl-2 Inhibitor are used in the treatment of Acute Myeloid Leukemia (AML)?

Updated: May 26, 2020
  • Author: Karen Seiter, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

Bcl-2 Inhibitor

Overexpression of Bcl-2 has been demonstrated in AML cells, where it mediates tumor cell survival and has been associated with resistance to chemotherapeutic agents.

Venetoclax (Venclexta)

Selective inhibitor of the B-cell lymphoma 2 (Bcl-2) regulator protein, an antiapoptotic protein. Venetoclax helps restore the process of apoptosis by binding directly to Bcl-2 protein. It is indicated for newly diagnosed AML in adults aged 75 years or older, or adults who have comorbidities that preclude use of intensive induction chemotherapy. It is used in combination with azacytidine, or decitabine, or low-dose cytarabine.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!